Targeting the Molecular and Cellular Interactions of the Bone Marrow Niche in Immunologic Disease

  • Jaime M. Brozowski
  • Matthew J. Billard
  • Teresa K. Tarrant
Part of the following topical collections:
  1. Topical Collection on Autoimmunity


Recent investigations have expanded our knowledge of the regulatory bone marrow (BM) niche, which is critical in maintaining and directing hematopoietic stem cell (HSC) self-renewal and differentiation. Osteoblasts, mesenchymal stem cells (MSCs), and CXCL12-abundant reticular (CAR) cells are niche components in close association with HSCs and have been more clearly defined in immune cell function and homeostasis. Importantly, cellular inhabitants of the BM niche signal through G protein-coupled surface receptors (GPCRs) for various appropriate immune functions. In this article, recent literature on BM niche inhabitants (HSCs, osteoblasts, MSCs, CAR cells) and their GPCR mechanistic interactions are reviewed for better understanding of the BM cells involved in immune development, immunologic disease, and current immune reconstitution therapies.


Bone marrow (BM) Endosteal niche Perivascular niche Hematopoietic stem cells (HSCs) Mesenchymal stem cells (MSCs) CXCL12-abundant reticular (CAR) cells Osteoblasts G protein-coupled receptors (GPCRs) G protein-coupled receptor kinase (GRK) Hematopoietic cell transplantation (HCT) Hematopoietic stem cell transplantation (HSCT) CXCL12 CXCR4 Sphingosine-1-phosphate (S1P) Sphingosine-1-phosphate receptor (S1PR) Parathyroid hormone (PTH) Parathyroid hormone receptor (PTH1R) Granulocyte colony-stimulating factor (G-CSF) AMD3100 FTY720 SEW2871 


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    McCulloch EA, Till JE. The radiation sensitivity of normal mouse bone marrow cells, determined by quantitative marrow transplantation into irradiated mice. Radiat Res. 1960;13:115–25.PubMedGoogle Scholar
  2. 2.
    Becker AJ, Mc CE, Till JE. Cytological demonstration of the clonal nature of spleen colonies derived from transplanted mouse marrow cells. Nature. 1963;197:452–4.PubMedGoogle Scholar
  3. 3.
    Friedenstein AJ et al. Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation. 1968;6(2):230–47.PubMedGoogle Scholar
  4. 4.
    McCulloch EA, Till JE. Proliferation of Hemopoietic Colony-Forming Cells Transplanted into Irradiated Mice. Radiat Res. 1964;22:383–97.PubMedGoogle Scholar
  5. 5.
    Till JE, Mc CE. A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat Res. 1961;14:213–22.PubMedGoogle Scholar
  6. 6.
    Friedenstein AJ. Precursor cells of mechanocytes. Int Rev Cytol. 1976;47:327–59.PubMedGoogle Scholar
  7. 7.
    Friedenstein AJ, Chailakhjan RK, Lalykina KS. The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Tissue Kinet. 1970;3(4):393–403.PubMedGoogle Scholar
  8. 8.
    Friedenstein AJ et al. Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. Transplantation. 1974;17(4):331–40.PubMedGoogle Scholar
  9. 9.
    Friedenstein AJ et al. Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. Exp Hematol. 1974;2(2):83–92.PubMedGoogle Scholar
  10. 10.
    Friedenstein AJ et al. Origin of bone marrow stromal mechanocytes in radiochimeras and heterotopic transplants. Exp Hematol. 1978;6(5):440–4.PubMedGoogle Scholar
  11. 11.
    Luria EA, Panasyuk AF, Friedenstein AY. Fibroblast colony formation from monolayer cultures of blood cells. Transfusion. 1971;11(6):345–9.PubMedGoogle Scholar
  12. 12.
    Scadden DT. The stem-cell niche as an entity of action. Nature. 2006;441(7097):1075–9.PubMedGoogle Scholar
  13. 13.
    Schofield R. The relationship between the spleen colony-forming cell and the haemopoietic stem cell. Blood Cells. 1978;4(1–2):7–25.PubMedGoogle Scholar
  14. 14.
    Thomas ED. The Nobel Lectures in Immunology. The Nobel Prize for Physiology or Medicine, 1990. Bone marrow transplantation--past, present and future. Scand J Immunol. 1994;39(4):339–45.PubMedGoogle Scholar
  15. 15.
    Gatti RA et al. Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet. 1968;2(7583):1366–9.PubMedGoogle Scholar
  16. 16.
    Griffith LM et al. Target populations in allogeneic hematopoietic cell transplantation for autoimmune diseases–a workshop accompanying: cellular therapy for treatment of autoimmune diseases, basic science and clinical studies, including new developments in hematopoietic and mesenchymal stem cell therapy. Biol Blood Marrow Transplant. 2006;12(6):688–90.PubMedGoogle Scholar
  17. 17.
    •• Gratwohl A et al. Quantitative and qualitative differences in use and trends of hematopoietic stem cell transplantation: a Global Observational Study. Haematologica. 2013;98(8):1282–90. Extensive report on worldwide analysis of HCT and HSCT during a 3-year period: 2006–2008.PubMedGoogle Scholar
  18. 18.
    Armitage JO. Bone marrow transplantation. N Engl J Med. 1994;330(12):827–38.PubMedGoogle Scholar
  19. 19.
    Atkins HL et al. Autologous hematopoietic stem cell transplantation for autoimmune disease–is it now ready for prime time? Biol Blood Marrow Transplant. 2012;18(1 Suppl):S177–83.PubMedGoogle Scholar
  20. 20.
    Gratwohl A et al. Hematopoietic stem cell transplantation: a global perspective. JAMA. 2010;303(16):1617–24.PubMedCentralPubMedGoogle Scholar
  21. 21.
    Petersdorf EW. The major histocompatibility complex: a model for understanding graft-versus-host disease. Blood. 2013;122(11):1863–72.PubMedGoogle Scholar
  22. 22.
    Jansen J et al. Transplantation of hematopoietic stem cells from the peripheral blood. J Cell Mol Med. 2005;9(1):37–50.PubMedGoogle Scholar
  23. 23.
    Pavletic ZS et al. Hematopoietic recovery after allogeneic blood stem-cell transplantation compared with bone marrow transplantation in patients with hematologic malignancies. J Clin Oncol. 1997;15(4):1608–16.PubMedGoogle Scholar
  24. 24.
    Mancardi G, Saccardi R. Autologous haematopoietic stem-cell transplantation in multiple sclerosis. Lancet Neurol. 2008;7(7):626–36.PubMedGoogle Scholar
  25. 25.
    Sullivan KM, Muraro P, Tyndall A. Hematopoietic cell transplantation for autoimmune disease: updates from Europe and the United States. Biol Blood Marrow Transplant. 2010;16(1 Suppl):S48–56.PubMedCentralPubMedGoogle Scholar
  26. 26.
    Milanetti F et al. Autologous hematopoietic stem cell transplantation for systemic sclerosis. Curr Stem Cell Res Ther. 2011;6(1):16–28.PubMedGoogle Scholar
  27. 27.
    Naraghi K, van Laar JM. Update on stem cell transplantation for systemic sclerosis: recent trial results. Curr Rheumatol Rep. 2013;15(5):326.PubMedGoogle Scholar
  28. 28.
    •• Frenette PS et al. Mesenchymal stem cell: keystone of the hematopoietic stem cell niche and a stepping-stone for regenerative medicine. Annu Rev Immunol. 2013;31:285–316. Vast review on defining MSCs and discussing their role in the BM niche, involvement in immune function, and therapeutic applications.PubMedGoogle Scholar
  29. 29.
    Masuda S et al. Cotransplantation with MSCs improves engraftment of HSCs after autologous intra-bone marrow transplantation in nonhuman primates. Exp Hematol. 2009;37(10):1250–1257 e1.PubMedGoogle Scholar
  30. 30.
    Cheshier SH, Prohaska SS, Weissman IL. The effect of bleeding on hematopoietic stem cell cycling and self-renewal. Stem Cells Dev. 2007;16(5):707–17.PubMedGoogle Scholar
  31. 31.
    Baldridge MT, King KY, Goodell MA. Inflammatory signals regulate hematopoietic stem cells. Trends Immunol. 2011;32(2):57–65.PubMedCentralPubMedGoogle Scholar
  32. 32.
    Seita J, Weissman IL. Hematopoietic stem cell: self-renewal versus differentiation. Wiley Interdiscip Rev Syst Biol Med. 2010;2(6):640–53.PubMedCentralPubMedGoogle Scholar
  33. 33.
    Trumpp A, Essers M, Wilson A. Awakening dormant haematopoietic stem cells. Nat Rev Immunol. 2010;10(3):201–9.PubMedGoogle Scholar
  34. 34.
    Wilson A et al. Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair. Cell. 2008;135(6):1118–29.PubMedGoogle Scholar
  35. 35.
    Taichman RS, Reilly MJ, Emerson SG. Human osteoblasts support human hematopoietic progenitor cells in vitro bone marrow cultures. Blood. 1996;87(2):518–24.PubMedGoogle Scholar
  36. 36.
    Taichman RS, Emerson SG. Human osteoblasts support hematopoiesis through the production of granulocyte colony-stimulating factor. J Exp Med. 1994;179(5):1677–82.PubMedGoogle Scholar
  37. 37.
    Calvi LM et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature. 2003;425(6960):841–6.PubMedGoogle Scholar
  38. 38.
    Zhang J et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature. 2003;425(6960):836–41.PubMedGoogle Scholar
  39. 39.
    Visnjic D et al. Hematopoiesis is severely altered in mice with an induced osteoblast deficiency. Blood. 2004;103(9):3258–64.PubMedGoogle Scholar
  40. 40.
    •• Doze VA, Perez DM. GPCRs in stem cell function. Prog Mol Biol Transl Sci. 2013;115:175–216. Thorough review on various G protein-coupled receptors and embryonic, induced pluripotent, cancer, and adult stem cells.PubMedCentralPubMedGoogle Scholar
  41. 41.
    Sacchetti B et al. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell. 2007;131(2):324–36.PubMedGoogle Scholar
  42. 42.
    Mendez-Ferrer S et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature. 2010;466(7308):829–34.PubMedCentralPubMedGoogle Scholar
  43. 43.
    Rostovskaya M, Anastassiadis K. Differential expression of surface markers in mouse bone marrow mesenchymal stromal cell subpopulations with distinct lineage commitment. PLoS One. 2012;7(12):e51221.PubMedCentralPubMedGoogle Scholar
  44. 44.
    Siegel G et al. Phenotype, donor age and gender affect function of human bone marrow-derived mesenchymal stromal cells. BMC Med. 2013;11:146.PubMedCentralPubMedGoogle Scholar
  45. 45.
    Tokoyoda K et al. Cellular niches controlling B lymphocyte behavior within bone marrow during development. Immunity. 2004;20(6):707–18.PubMedGoogle Scholar
  46. 46.
    Sugiyama T et al. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity. 2006;25(6):977–88.PubMedGoogle Scholar
  47. 47.
    Sugiyama T, Nagasawa T. Bone marrow niches for hematopoietic stem cells and immune cells. Inflamm Allergy Drug Targets. 2012;11(3):201–6.PubMedCentralPubMedGoogle Scholar
  48. 48.
    Nagasawa T, Kikutani H, Kishimoto T. Molecular cloning and structure of a pre-B-cell growth-stimulating factor. Proc Natl Acad Sci U S A. 1994;91(6):2305–9.PubMedCentralPubMedGoogle Scholar
  49. 49.
    Nagasawa T et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature. 1996;382(6592):635–8.PubMedGoogle Scholar
  50. 50.
    Nagasawa T. The chemokine CXCL12 and regulation of HSC and B lymphocyte development in the bone marrow niche. Adv Exp Med Biol. 2007;602:69–75.PubMedGoogle Scholar
  51. 51.
    Kohara H et al. Development of plasmacytoid dendritic cells in bone marrow stromal cell niches requires CXCL12-CXCR4 chemokine signaling. Blood. 2007;110(13):4153–60.PubMedGoogle Scholar
  52. 52.
    Noda M et al. CXCL12-CXCR4 chemokine signaling is essential for NK-cell development in adult mice. Blood. 2011;117(2):451–8.PubMedGoogle Scholar
  53. 53.
    Omatsu Y et al. The essential functions of adipo-osteogenic progenitors as the hematopoietic stem and progenitor cell niche. Immunity. 2010;33(3):387–99.PubMedGoogle Scholar
  54. 54.
    Zhu J et al. Osteoblasts support B-lymphocyte commitment and differentiation from hematopoietic stem cells. Blood. 2007;109(9):3706–12.PubMedGoogle Scholar
  55. 55.
    Kiel MJ et al. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell. 2005;121(7):1109–21.PubMedGoogle Scholar
  56. 56.
    Pinho S et al. PDGFRalpha and CD51 mark human nestin+ sphere-forming mesenchymal stem cells capable of hematopoietic progenitor cell expansion. J Exp Med. 2013;210(7):1351–67.PubMedCentralPubMedGoogle Scholar
  57. 57.
    • Ding L, Morrison SJ. Haematopoietic stem cells and early lymphoid progenitors occupy distinct bone marrow niches. Nature. 2013;495(7440):231–5. Demonstrates that different stem and progenitor cells occupy distinct BM niches—simultaneous study; see Greenbaum et al.PubMedCentralPubMedGoogle Scholar
  58. 58.
    Hsu YC, Fuchs E. A family business: stem cell progeny join the niche to regulate homeostasis. Nat Rev Mol Cell Biol. 2012;13(2):103–14.PubMedCentralPubMedGoogle Scholar
  59. 59.
    • Greenbaum A et al. CXCL12 in early mesenchymal progenitors is required for haematopoietic stem-cell maintenance. Nature. 2013;495(7440):227–30. Demonstrates different stem and progenitor cells occupy distinct BM niches— simultaneous study; see Ding et al.PubMedCentralPubMedGoogle Scholar
  60. 60.
    Heazlewood SY et al. Megakaryocytes co-localise with hemopoietic stem cells and release cytokines that up-regulate stem cell proliferation. Stem Cell Res. 2013;11(2):782–92.PubMedGoogle Scholar
  61. 61.
    Calvi LM, Link DC. Cellular Complexity of the Bone Marrow Hematopoietic Stem Cell Niche. Calcif Tissue Int. 2013.Google Scholar
  62. 62.
    DeWire SM et al. Beta-arrestins and cell signaling. Annu Rev Physiol. 2007;69:483–510.PubMedGoogle Scholar
  63. 63.
    Goltzman D. Studies on the mechanisms of the skeletal anabolic action of endogenous and exogenous parathyroid hormone. Arch Biochem Biophys. 2008;473(2):218–24.PubMedGoogle Scholar
  64. 64.
    Calvi LM. Osteoblastic activation in the hematopoietic stem cell niche. Ann N Y Acad Sci. 2006;1068:477–88.PubMedGoogle Scholar
  65. 65.
    Smith JN, Calvi LM. Concise review: Current concepts in bone marrow microenvironmental regulation of hematopoietic stem and progenitor cells. Stem Cells. 2013;31(6):1044–50.PubMedGoogle Scholar
  66. 66.
    Brunner S et al. Primary hyperparathyroidism is associated with increased circulating bone marrow-derived progenitor cells. Am J Physiol Endocrinol Metab. 2007;293(6):E1670–5.PubMedGoogle Scholar
  67. 67.
    Calvi LM et al. Osteoblastic expansion induced by parathyroid hormone receptor signaling in murine osteocytes is not sufficient to increase hematopoietic stem cells. Blood. 2012;119(11):2489–99.PubMedGoogle Scholar
  68. 68.
    Chemokine/chemokine receptor nomenclature. Cytokine. 2003;21(1):48–9.Google Scholar
  69. 69.
    Vila-Coro AJ et al. The chemokine SDF-1alpha triggers CXCR4 receptor dimerization and activates the JAK/STAT pathway. Faseb J. 1999;13(13):1699–710.PubMedGoogle Scholar
  70. 70.
    Forster R et al. Intracellular and surface expression of the HIV-1 coreceptor CXCR4/fusin on various leukocyte subsets: rapid internalization and recycling upon activation. J Immunol. 1998;160(3):1522–31.PubMedGoogle Scholar
  71. 71.
    Wynn RF et al. A small proportion of mesenchymal stem cells strongly expresses functionally active CXCR4 receptor capable of promoting migration to bone marrow. Blood. 2004;104(9):2643–5.PubMedGoogle Scholar
  72. 72.
    Sordi V et al. Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets. Blood. 2005;106(2):419–27.PubMedGoogle Scholar
  73. 73.
    Dar A, Kollet O, Lapidot T. Mutual, reciprocal SDF-1/CXCR4 interactions between hematopoietic and bone marrow stromal cells regulate human stem cell migration and development in NOD/SCID chimeric mice. Exp Hematol. 2006;34(8):967–75.PubMedGoogle Scholar
  74. 74.
    Premont RT, Inglese J, Lefkowitz RJ. Protein kinases that phosphorylate activated G protein-coupled receptors. Faseb J. 1995;9(2):175–82.PubMedGoogle Scholar
  75. 75.
    Balabanian K et al. WHIM syndromes with different genetic anomalies are accounted for by impaired CXCR4 desensitization to CXCL12. Blood. 2005;105(6):2449–57.PubMedGoogle Scholar
  76. 76.
    Balabanian K et al. Leukocyte analysis from WHIM syndrome patients reveals a pivotal role for GRK3 in CXCR4 signaling. J Clin Invest. 2008;118(3):1074–84.PubMedCentralPubMedGoogle Scholar
  77. 77.
    Mueller W, et al. Hierarchical organization of multi-site phosphorylation at the CXCR4 C terminus. PLoS One. 8(5):e64975.Google Scholar
  78. 78.
    Tarrant TK, et al. G protein-coupled receptor kinase-3-deficient mice exhibit WHIM syndrome features and attenuated inflammatory responses. J Leukoc Biol.Google Scholar
  79. 79.
    Pappu R et al. Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science. 2007;316(5822):295–8.PubMedGoogle Scholar
  80. 80.
    Ito K et al. Lack of sphingosine 1-phosphate-degrading enzymes in erythrocytes. Biochem Biophys Res Commun. 2007;357(1):212–7.PubMedGoogle Scholar
  81. 81.
    Venkataraman K et al. Extracellular export of sphingosine kinase-1a contributes to the vascular S1P gradient. Biochem J. 2006;397(3):461–71.PubMedGoogle Scholar
  82. 82.
    Hisano Y et al. Mouse SPNS2 functions as a sphingosine-1-phosphate transporter in vascular endothelial cells. PLoS One. 2012;7(6):e38941.PubMedCentralPubMedGoogle Scholar
  83. 83.
    Fukuhara S et al. The sphingosine-1-phosphate transporter Spns2 expressed on endothelial cells regulates lymphocyte trafficking in mice. J Clin Invest. 2012;122(4):1416–26.PubMedCentralPubMedGoogle Scholar
  84. 84.
    Yatomi Y et al. Sphingosine 1-phosphate: synthesis and release. Prostaglandins. 2001;64(1–4):107–22.PubMedGoogle Scholar
  85. 85.
    Bendall LJ, Basnett J. Role of sphingosine 1-phosphate in trafficking and mobilization of hematopoietic stem cells. Curr Opin Hematol. 2013;20(4):281–8.PubMedGoogle Scholar
  86. 86.
    Billich A et al. Partial deficiency of sphingosine-1-phosphate lyase confers protection in experimental autoimmune encephalomyelitis. PLoS One. 2013;8(3):e59630.PubMedCentralPubMedGoogle Scholar
  87. 87.
    • Golan K, Kollet O, Lapidot T. Dynamic cross talk between S1P and CXCL12 regulates hamatopoietic stem cells migration, development, and bone remodeling. Pharmaceuticals. 2013;6(9):1145–69. Review that highlights the concept of synchronized S1P/S1PR and CXCL12/CXCR4 interactions in HSC mobilization.PubMedGoogle Scholar
  88. 88.
    Kimura T et al. The sphingosine 1-phosphate receptor agonist FTY720 supports CXCR4-dependent migration and bone marrow homing of human CD34+ progenitor cells. Blood. 2004;103(12):4478–86.PubMedGoogle Scholar
  89. 89.
    Meriane M et al. Cooperation of matrix metalloproteinases with the RhoA/Rho kinase and mitogen-activated protein kinase kinase-1/extracellular signal-regulated kinase signaling pathways is required for the sphingosine-1-phosphate-induced mobilization of marrow-derived stromal cells. Stem Cells. 2006;24(11):2557–65.PubMedGoogle Scholar
  90. 90.
    Zhang L et al. A novel role of sphingosine 1-phosphate receptor S1pr1 in mouse thrombopoiesis. J Exp Med. 2012;209(12):2165–81.PubMedCentralPubMedGoogle Scholar
  91. 91.
    Maceyka M et al. Sphingosine-1-phosphate signaling and its role in disease. Trends Cell Biol. 2012;22(1):50–60.PubMedCentralPubMedGoogle Scholar
  92. 92.
    Bagdanoff JT et al. Inhibition of sphingosine 1-phosphate lyase for the treatment of rheumatoid arthritis: discovery of (E)-1-(4-((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-1H-imidazol-2-yl)ethanone oxime (LX2931) and (1R,2S,3R)-1-(2-(isoxazol-3-yl)-1H-imidazol-4-yl)butane-1,2,3,4-tetraol (LX2932). J Med Chem. 2010;53(24):8650–62.PubMedGoogle Scholar
  93. 93.
    Bagdanoff JT et al. Inhibition of sphingosine-1-phosphate lyase for the treatment of autoimmune disorders. J Med Chem. 2009;52(13):3941–53.PubMedGoogle Scholar
  94. 94.
    Arnon TI et al. GRK2-dependent S1PR1 desensitization is required for lymphocytes to overcome their attraction to blood. Science. 2011;333(6051):1898–903.PubMedCentralPubMedGoogle Scholar
  95. 95.
    Ryu JM et al. Sphingosine-1-phosphate-induced Flk-1 transactivation stimulates mouse embryonic stem cell proliferation through S1P/S1P-dependent beta-arrestin/c-Src pathways. Stem Cell Res. 2013;12(1):69–85.PubMedGoogle Scholar
  96. 96.
    Golan K et al. S1P promotes murine progenitor cell egress and mobilization via S1P1-mediated ROS signaling and SDF-1 release. Blood. 2012;119(11):2478–88.PubMedGoogle Scholar
  97. 97.
    Bonig H, Papayannopoulou T. Hematopoietic stem cell mobilization: updated conceptual renditions. Leukemia. 2013;27(1):24–31.PubMedCentralPubMedGoogle Scholar
  98. 98.
    Motabi IH, DiPersio JF. Advances in stem cell mobilization. Blood Rev. 2012;26(6):267–78.PubMedGoogle Scholar
  99. 99.
    Arcese W, De Angelis G, Cerretti R. Granulocyte-mobilized bone marrow. Curr Opin Hematol. 2012;19(6):448–53.PubMedGoogle Scholar
  100. 100.
    Levesque JP et al. Vascular cell adhesion molecule-1 (CD106) is cleaved by neutrophil proteases in the bone marrow following hematopoietic progenitor cell mobilization by granulocyte colony-stimulating factor. Blood. 2001;98(5):1289–97.PubMedGoogle Scholar
  101. 101.
    Levesque JP et al. Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J Clin Invest. 2003;111(2):187–96.PubMedCentralPubMedGoogle Scholar
  102. 102.
    Levesque JP et al. Characterization of hematopoietic progenitor mobilization in protease-deficient mice. Blood. 2004;104(1):65–72.PubMedGoogle Scholar
  103. 103.
    Devine SM et al. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin’s lymphoma. J Clin Oncol. 2004;22(6):1095–102.PubMedGoogle Scholar
  104. 104.
    DiPersio JF et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin’s lymphoma. J Clin Oncol. 2009;27(28):4767–73.PubMedGoogle Scholar
  105. 105.
    Maziarz RT et al. Plerixafor plus granulocyte colony-stimulating factor improves the mobilization of hematopoietic stem cells in patients with non-Hodgkin lymphoma and low circulating peripheral blood CD34+ cells. Biol Blood Marrow Transplant. 2013;19(4):670–5.PubMedGoogle Scholar
  106. 106.
    Sison EA, Brown P. The bone marrow microenvironment and leukemia: biology and therapeutic targeting. Expert Rev Hematol. 2011;4(3):271–83.PubMedCentralPubMedGoogle Scholar
  107. 107.
    Tavor S et al. The CXCR4 antagonist AMD3100 impairs survival of human AML cells and induces their differentiation. Leukemia. 2008;22(12):2151–5158.PubMedGoogle Scholar
  108. 108.
    Kang Y et al. Selective enhancement of donor hematopoietic cell engraftment by the CXCR4 antagonist AMD3100 in a mouse transplantation model. PLoS One. 2010;5(6):e11316.PubMedCentralPubMedGoogle Scholar
  109. 109.
    Dale DC et al. The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome. Blood. 2011;118(18):4963–6.PubMedGoogle Scholar
  110. 110.
    Ballen KK et al. Phase I trial of parathyroid hormone to facilitate stem cell mobilization. Biol Blood Marrow Transplant. 2007;13(7):838–43.PubMedGoogle Scholar
  111. 111.
    Ballen K et al. Phase II trial of parathyroid hormone after double umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2012;18(12):1851–8.PubMedCentralPubMedGoogle Scholar
  112. 112.
    Whetton AD et al. Lysophospholipids synergistically promote primitive hematopoietic cell chemotaxis via a mechanism involving Vav 1. Blood. 2003;102(8):2798–802.PubMedGoogle Scholar
  113. 113.
    Massberg S et al. Immunosurveillance by hematopoietic progenitor cells trafficking through blood, lymph, and peripheral tissues. Cell. 2007;131(5):994–1008.PubMedCentralPubMedGoogle Scholar
  114. 114.
    Halin C et al. The S1P-analog FTY720 differentially modulates T-cell homing via HEV: T-cell-expressed S1P1 amplifies integrin activation in peripheral lymph nodes but not in Peyer patches. Blood. 2005;106(4):1314–22.PubMedGoogle Scholar
  115. 115.
    Maeda Y et al. Sphingosine 1-phosphate receptor type 1 regulates egress of mature T cells from mouse bone marrow. Int Immunol. 2010;22(6):515–25.PubMedGoogle Scholar
  116. 116.
    Pereira JP, Xu Y, Cyster JG. A role for S1P and S1P1 in immature-B cell egress from mouse bone marrow. PLoS One. 2010;5(2):e9277.PubMedCentralPubMedGoogle Scholar
  117. 117.
    Allende ML et al. Sphingosine-1-phosphate lyase deficiency produces a pro-inflammatory response while impairing neutrophil trafficking. J Biol Chem. 2011;286(9):7348–58.PubMedGoogle Scholar
  118. 118.
    Juarez JG et al. Sphingosine-1-phosphate facilitates trafficking of hematopoietic stem cells and their mobilization by CXCR4 antagonists in mice. Blood. 2012;119(3):707–16.PubMedGoogle Scholar
  119. 119.
    McDermott DH, et al. The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome. Blood. 118(18):4957–62.Google Scholar
  120. 120.
    Song JS, et al. Inhibitory effect of CXC chemokine receptor 4 antagonist AMD3100 on bleomycin induced murine pulmonary fibrosis. Exp Mol Med. 42(6):465–72.Google Scholar
  121. 121.
    Makino H, et al. Antifibrotic effects of CXCR4 antagonist in bleomycin-induced pulmonary fibrosis in mice. J Med Invest. 60(1–2):127–37.Google Scholar
  122. 122.
    Yannaki E, et al. Hematopoietic stem cell mobilization for gene therapy of adult patients with severe beta-thalassemia: results of clinical trials using G-CSF or plerixafor in splenectomized and nonsplenectomized subjects. Mol Ther. 20(1):230–8.Google Scholar
  123. 123.
    Pulliam AC et al. AMD3100 synergizes with G-CSF to mobilize repopulating stem cells in Fanconi anemia knockout mice. Exp Hematol. 2008;36(9):1084–90.PubMedGoogle Scholar
  124. 124.
    Nishimura Y, et al. CXCR4 antagonist AMD3100 accelerates impaired wound healing in diabetic mice. J Invest Dermatol. 132(3 Pt 1):711–20.Google Scholar
  125. 125.
    MacFarland R, et al. A pharmacokinetic study of plerixafor in subjects with varying degrees of renal impairment. Biol Blood Marrow Transplant. 16(1):95–101.Google Scholar
  126. 126.
    Uy GL, et al. A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood. 119(17):3917–24.Google Scholar
  127. 127.
    DiPersio JF et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009;113(23):5720–6.PubMedGoogle Scholar
  128. 128.
    Cashen A et al. A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma. Biol Blood Marrow Transplant. 2008;14(11):1253–61.PubMedGoogle Scholar
  129. 129.
    Hubel K, et al. European data on stem cell mobilization with plerixafor in non-Hodgkin’s lymphoma, Hodgkin’s lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization. Bone Marrow Transplant. 47(8):1046–50.Google Scholar
  130. 130.
    Attolico I, et al. Plerixafor added to chemotherapy plus G-CSF is safe and allows adequate PBSC collection in predicted poor mobilizer patients with multiple myeloma or lymphoma. Biol Blood Marrow Transplant. 18(2):241–9.Google Scholar
  131. 131.
    Rubin JB et al. A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci U S A. 2003;100(23):13513–8.PubMedCentralPubMedGoogle Scholar
  132. 132.
    Redjal N et al. CXCR4 inhibition synergizes with cytotoxic chemotherapy in gliomas. Clin Cancer Res. 2006;12(22):6765–71.PubMedGoogle Scholar
  133. 133.
    Vives S, et al. Plerixafor plus G-CSF in combination with chemotherapy for stem cell mobilization in a pediatric patient with Ewing’s sarcoma. J Clin Apher. 27(5):260–2.Google Scholar
  134. 134.
    Devine SM et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood. 2008;112(4):990–8.PubMedGoogle Scholar
  135. 135.
    Shepherd RM et al. Angiogenic cells can be rapidly mobilized and efficiently harvested from the blood following treatment with AMD3100. Blood. 2006;108(12):3662–7.PubMedGoogle Scholar
  136. 136.
    Kappos L et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med. 2006;355(11):1124–40.PubMedGoogle Scholar
  137. 137.
    Kappos L, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 362(5):387–401.Google Scholar
  138. 138.
    Comi G, et al. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. Mult Scler. 16(2):197–207.Google Scholar
  139. 139.
    O’Connor P et al. Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology. 2009;72(1):73–9.PubMedGoogle Scholar
  140. 140.
    Kurose S et al. Effects of FTY720, a novel immunosuppressant, on experimental autoimmune uveoretinitis in rats. Exp Eye Res. 2000;70(1):7–15.PubMedGoogle Scholar
  141. 141.
    Commodaro AG, et al. Evaluation of experimental autoimmune uveitis in mice treated with FTY720. Invest Ophthalmol Vis Sci. 51(5):2568–74.Google Scholar
  142. 142.
    Copland DA, et al. Therapeutic dosing of fingolimod (FTY720) prevents cell infiltration, rapidly suppresses ocular inflammation, and maintains the blood-ocular barrier. Am J Pathol. 180(2):672–81.Google Scholar
  143. 143.
    Zhang Z et al. Distribution of Foxp3(+) T-regulatory cells in experimental autoimmune neuritis rats. Exp Neurol. 2009;216(1):75–82.PubMedGoogle Scholar
  144. 144.
    Sawicka E et al. Inhibition of Th1- and Th2-mediated airway inflammation by the sphingosine 1-phosphate receptor agonist FTY720. J Immunol. 2003;171(11):6206–14.PubMedGoogle Scholar
  145. 145.
    Budde K et al. First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J Am Soc Nephrol. 2002;13(4):1073–83.PubMedGoogle Scholar
  146. 146.
    Schmouder R, Hariry S, David OJ. Placebo-controlled study of the effects of fingolimod on cardiac rate and rhythm and pulmonary function in healthy volunteers. Eur J Clin Pharmacol. 68(4):355–62.Google Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Jaime M. Brozowski
    • 1
    • 3
  • Matthew J. Billard
    • 2
    • 4
  • Teresa K. Tarrant
    • 1
    • 2
    • 4
  1. 1.Department of Microbiology and ImmunologyUniversity of North CarolinaChapel HillUSA
  2. 2.Thurston Arthritis Research Center and the Department of Medicine, Division of Rheumatology, Allergy, and ImmunologyUniversity of North Carolina School of MedicineChapel HillUSA
  3. 3.The University of North Carolina at Chapel HillChapel HillUSA
  4. 4.Thurston Arthritis Research CenterThe University of North Carolina at Chapel HillChapel HillUSA

Personalised recommendations